ER degradation-enhancing alpha-mannosidase-like protein 1 (EDEM1)

ER degradation-enhancing alpha-mannosidase-like protein 1 (EDEM1) is a type II transmembrane protein localized in the endoplasmic reticulum and is a crucial component of the ER-associated degradation (ERAD) pathway, which eliminates misfolded glycoproteins from the ER. Although it shares sequence similarity with class I alpha-mannosidases, EDEM1 exhibits low or no canonical enzymatic mannosidase activity but extracted misfolded glycoproteins from the calnexin cycle to facilitate their targeting to retrotranslocation and proteasomal degradation. EDEM1 is upregulated by ER stress and the unfolded protein response (UPR), playing a pivotal role in the cellular quality control mechanisms to maintain protein homeostasis. Its dysregulation has been associated with certain diseases such as cancers and congenital disorders involving protein folding or glycosylation defects. If more detailed references or pharmacology are required, further exploration in dedicated drug-targeting databases and specialized pharmaceutical resources is necessary.

Other names

EDEM1ER degradation enhancer, mannosidase alpha-like 1ER degradation-enhancing alpha-mannosidase-like 1Edem (in mouse and some literature)ER degradation enhancing alpha-mannosidase like protein 1

Drugs targeting the unfolded protein response or ER-associated degradation (hypothetical): would act by modulating ER stress signaling, potentially altering EDEM1 abundance or activity. No drugs directly target EDEM1 according to current references.